Abstract
DNA methylation and histone acetylation are two most studied epigenetic markers. Aberrant methylation of gene promoter regions and histone tail lysine residue modification through acetylation and methylation play a key role in malignant disorders. Two DNA methyltransferase inhibitors, azacitidine and decitabine, have been licensed for clinical therapy for patients with myelodysplastic syndrome. New hypomethylating agents, zebularine and isothiocyanates, are in various stages of development for cancer therapy. In this review we summarize recent clinical developments on novel hypomethylating agents and new regimens from clinical trials for epigenetic therapy of cancer.
Keywords: Epigenetic, chromatin, DNA hypomethylation, azacitidine, decitabine, zebularine
Current Cancer Drug Targets
Title: Clinical Advances in Hypomethylating Agents Targeting Epigenetic Pathways
Volume: 10 Issue: 5
Author(s): S. Cang, Q. Lu, Y. Ma and D. Liu
Affiliation:
Keywords: Epigenetic, chromatin, DNA hypomethylation, azacitidine, decitabine, zebularine
Abstract: DNA methylation and histone acetylation are two most studied epigenetic markers. Aberrant methylation of gene promoter regions and histone tail lysine residue modification through acetylation and methylation play a key role in malignant disorders. Two DNA methyltransferase inhibitors, azacitidine and decitabine, have been licensed for clinical therapy for patients with myelodysplastic syndrome. New hypomethylating agents, zebularine and isothiocyanates, are in various stages of development for cancer therapy. In this review we summarize recent clinical developments on novel hypomethylating agents and new regimens from clinical trials for epigenetic therapy of cancer.
Export Options
About this article
Cite this article as:
Cang S., Lu Q., Ma Y. and Liu D., Clinical Advances in Hypomethylating Agents Targeting Epigenetic Pathways, Current Cancer Drug Targets 2010; 10 (5) . https://dx.doi.org/10.2174/156800910791517217
DOI https://dx.doi.org/10.2174/156800910791517217 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Overcoming Chemotherapy Resistance in High Grade Serous Ovarian Cancer
Current Cancer Therapy Reviews An Update on the Extraneuronal Monoamine Transporter (EMT): Characteristics, Distribution and Regulation
Current Drug Metabolism Enhancing the Cytotoxic Activity of Novel Targeted Therapies – Is There a Role for a Combinatorial Approach?
Current Clinical Pharmacology Ultrasound Contrast Imaging in Cancer –Technical Aspects and Prospects
Current Molecular Imaging (Discontinued) Colchicine: An Ancient Drug with Multiple Benefits
Current Pharmaceutical Design Activities of Venom Proteins and Peptides with Possible Therapeutic Applications from Bees and WASPS
Protein & Peptide Letters Global View on Rare Diseases: A Mini Review
Current Medicinal Chemistry Editorial: Fighting Against Kidney Injury
Current Protein & Peptide Science Monoclonal Antibodies Targeting the Epidermal Growth Factor Receptor
Current Drug Targets Clear Cell Renal Cell Cancer Tumor-Propagating Cells: Molecular Characteristics
Current Signal Transduction Therapy Diagnostic Imaging of Hepatocellular Carcinoma - A Pictorial Essay
Current Medical Imaging Metastasis: Recent Discoveries and Novel Perioperative Treatment Strategies with Particular Interest in the Hemostatic Compound Desmopressin
Current Pharmaceutical Biotechnology Melatonin Regulates Angiogenic Factors under Hypoxia in Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Subject Index to Volume 5
Current Drug Targets Allelic Imbalances of the egfr Gene as Key Events in Breast Cancer Progression – the Concept of Committed Progenitor Cells
Current Cancer Drug Targets Interactions of Metal Ions with DNA, Its Constituents and Derivatives, which may be Relevant for Anticancer Research
Current Topics in Medicinal Chemistry Cancer Vaccines for Hormone/Growth Factor Immune Deprivation:A Feasible Approach for Cancer Treatment
Current Cancer Drug Targets Angiogenesis as a therapeutic target in breast cancer
Mini-Reviews in Medicinal Chemistry Common Cellular and Molecular Mechanisms Underlying Alzheimer’s Disease and Type 2 Diabetes: A Knowledge-Driven Approach
CNS & Neurological Disorders - Drug Targets CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies
Current Cancer Drug Targets